LumaCina offers Oral Morphine to New Zealanders

LumaCina, the pharmaceutical supply and marketing division of Bridgewest Perth Pharma, has announced an increase in the production of Oral Morphine to address a critical drug shortage in New Zealand. The shortage of this essential pain medication has raised significant concern, as many patients depend on it for effective pain management.

In response to this urgent need, LumaCina has been collaborating closely with Pharmac, the government agency in New Zealand responsible for pharmaceutical funding and access. LumaCina has invested considerably in expanding its production capabilities to ensure a stable and continuous supply of Oral Morphine to meet the demands.

Cyrus K. Mirsaidi, the Global CEO of LumaCina and Bridgewest Perth Pharma, emphasized the company's dedication to resolving the shortage. "We are deeply committed to addressing the shortage of Oral Morphine and ensuring that patients have access to the medication they need to alleviate pain and improve their quality of life. Through our collaboration with Pharmac, we are leveraging our collective expertise and resources to make a meaningful difference in the lives of patients across New Zealand," he stated.

Dr. Masood Tayebi, CEO and Founding Partner of Bridgewest Group, also highlighted the group's mission to positively impact public health. He remarked, "Making a positive impact on public health is paramount to our group's efforts. Through our ingenuity and resources, we aim to make a significant and lasting impact on the healthcare landscape and the lives of all."

Bridgewest Group has strategically expanded its life science ecosystem over the past year. This expansion includes enhancing research and development, manufacturing, and delivery capabilities. One notable achievement was acquiring the Pfizer Perth cGMP sterile injectable manufacturing plant. This acquisition led to the formation of Bridgewest Perth Pharma and its divisions, including the NovaCina CDMO division and LumaCina pharmaceutical supply division.

LumaCina, positioned as a global supplier and marketer of sterile injectable pharmaceuticals, is based in Perth, Australia. The company is aggressively broadening its capabilities, infrastructure, and industry partnerships. By doing so, LumaCina aims to develop a robust pipeline of high-quality injectable medications that are accessible and versatile. These products range from high potency drugs to multi-format vials and innovative blow-fill-seal products.

The company's commitment to addressing the Oral Morphine shortage in New Zealand underscores its broader mission to improve public health outcomes and enhance the quality of life for patients globally.